Our Founder, Marty Keiser, and our CEO, Elizabeth Cormier-May, were guests on Matthew Zachary’s OffScrip Media podcast, Out of Patients.

BioSpace | October 20, 2026 Mammogen announced the appointment of Rebecca D. Kaltman, M.D., Executive Director of the Inova Saville Cancer Screening and Prevention Center, as Principal Investigator for its KATELYN-ERIN clinical trial. The study will evaluate genTRU-breast™, Mammogen's RNA-powered blood-based assay being developed to support earlier breast cancer detection, particularly for women with dense breast tissue. Dr. Kaltman brings 20 years of experience in oncology, cancer prevention, and clinical research. Her leadership marks an important step as Mammogen advances its clinical validation efforts and explores how blood-based diagnostics can complement traditional breast imaging. Click Here to Read the Full Press Release →

Mammogen announced the appointment of Robert S. Epstein, M.D., M.S., to its Board of Directors as an Independent Director. Dr. Epstein brings decades of experience in genomics, precision medicine, and oncology diagnostics, including leadership roles with Illumina, Veracyte, and Decipher Biosciences. His appointment strengthens Mammogen's leadership as the company continues advancing genTRU-breast™, its RNA-powered blood-based assay designed to support earlier breast cancer detection, through clinical validation and toward commercialization. Click Here to Read the Full Press Release →